HCA HCA Healthcare, Inc. Common Stock
NYSE · Health Care · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Jul 28, 2026HCA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
HCA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
About HCA Healthcare, Inc. Common Stock Company overview from Wikipedia
HCA Healthcare, Inc. (historically known as Hospital Corporation of America) is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.
History
Early years
The Hospital Corporation of America (HCA) was founded in 1968 in Nashville, Tennessee, by Thomas F. Frist Sr., Thomas F. Frist Jr. and Jack C. Massey. The founders envisioned a company that would bring together hospitals to deliver patient-focused care while using the combined resources of the organization to strengthen hospitals and improve the practice of medicine. The company began with Nashville's Park View Hospital, which the elder Frist had founded in 1960 with other doctors and where he was chief executive.
The company included 11 hospitals when it filed its initial public offering on the New York Stock Exchange (NYSE) in 1969 and had 26 hospitals and 3,000 beds by the end of the year.
Growth and merger
The 1970s were characterized by rapid growth in the industry and for HCA Healthcare. In the early 1980s, the focus shifted to consolidation with HCA Healthcare acquiring General Care Corporation, General Health Services, Hospital Affiliates International and Health Care Corporation. By the end of 1981, the company operated 349 hospitals with more than 49,000 beds. Operating revenues had grown to $2.4 billion.
In 1987, HCA Healthcare, which had grown to operate 463 hospitals (255 owned and 208 managed), spun off HealthTrust, a privately owned, 104-hospital company. Believing its stock was undervalued, the company completed a $5.1 billion leveraged management buyout led by chairman Thomas F. Frist Jr. in 1988. HCA Healthcare re-emerged as a public company in 1992.
In February 1994, HCA Healthcare merged with Louisville, Kentucky-based Columbia Hospital Corporation, which earlier had acquired 73 hospitals of Galen Health Care from Humana,
to form Columbia/HCA Healthcare Corporation. Related names of note include HCA International and Health Corporation of America.
Columbia Hospital Corporation
In 1988, Rick Scott and Richard Rainwater each put up $125,000 in working capital in their new company, Columbia Hospital Corporation; they borrowed the remaining money needed to purchase two struggling hospitals in El Paso for $60 million. Then they acquired a neighboring hospital and shut it down. Within a year, the remaining two were doing much better. By the end of 1989, Columbia Hospital Corporation owned four hospitals with a total of 833 beds.
In 1992, Columbia made a stock purchase of Basic American Medical, which owned eight hospitals, primarily in southwestern Florida. In September 1993, Columbia did another stock purchase, worth $3.4 billion, of Galen Healthcare, which had been spun off by Humana Inc. several months earlier. At the time, Galen had approximately 90 hospitals. After the purchase, Galen stockholders had 82% of the stock in the combined company, with Scott still running the company.
Recent history
On November 17, 2006, HCA became a private company for the third time when it completed a merger in which the company was acquired by a private investor group including affiliates of Kohlberg Kravis Roberts and Bain Capital, together with Merrill Lynch and HCA Healthcare founder Thomas F. Frist Jr. The total transaction was valued at approximately $33 billion, making it the largest leveraged buyout in history at the time, eclipsing the 1989 buyout of RJR Nabisco.
In May 2010, HCA announced that the corporation would once again go public with an expected $4.6-billion IPO as HCA Holdings, Inc. In March 2011, HCA sold 126.2 million shares for $30 each, raising about $3.79 billion, at that time, the largest private-equity backed IPO in U.S. history. In May 2017, the corporation was renamed HCA Healthcare.
In December 2018, a historical marker was installed in the parking lot of HCA's Sarah Cannon Cancer Center in Nashville, formerly the location of HCA's first hospital, Park View Hospital.
In 2018, the company was ranked No. 67 in the 2019 Fortune 500 list of the largest United States corporations by total revenue.
In May 2021, the company finalized a deal with Google to develop healthcare algorithms using patient records. In August 2021, HCA announced a deal with venture capital firm General Catalyst to develop digital solutions to streamline workflows and improve patient care; as part of the deal, HCA sold its healthcare app development firm PatientKeeper to General Catalyst's portfolio company Commure.
In April 2022, HCA Healthcare announced a $1.5 million partnership with Florida International University's Nicole Wertheim college of Nursing and Health Sciences, to expand its facilities to address the national nursing shortage.
In October 2022, LCMC Health in partnership with Tulane University announced that it would acquire Tulane Medical Center, Lakeview Regional Medical Center, and Tulane Lakeside Hospital from HCA for $150 million pending regulatory approval.
In March 2024, it was announced HCA had completed the sale of West Hills Hospital and Medical Center and related assets in Los Angeles, California to UCLA Health, for an undisclosed amount.
Facilities
United States
As of 2024, HCA has 186 hospitals. They also report operating more than 2,400 additional sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics located in 20 U.S. states and in the United Kingdom. A significant portion of those hospitals are situated in Florida and Texas. As of 2022, HCA had 47 hospitals and 31 surgery centers in Florida, and 45 hospitals and 632 affiliated sites of care in Texas. In 2021, it announced plans to build 3 new hospitals in Florida. In 2022, The Dallas Morning News reported that HCA will build 5 new hospitals in Texas. They also have a strong presence in Tennessee, where it began. HCA had 13 hospitals there as of 2019.
Between 2003 and 2017, HCA did not enter any new markets. However, in July 2007, HCA sold its hospitals in Switzerland.
In 2017, HCA acquired the Memorial University Medical Center in Savannah, Georgia. That same year, they acquired three Houston, Texas, hospitals from Tenet Healthcare.
In 2019 they purchased Mission Health System which operates hospitals in North Carolina.
In January 2020, HCA Healthcare acquired Valify, a healthcare cost-management company. In May 2020, HCA acquired 49-bed Shands Starke (Fla.) Regional Medical Center and 25-bed Shands Live Oak (Fla.) Regional Medical Center from CHS. HCA is operating the two facilities as off-campus emergency departments of Lake City (Fla.) Medical Center and North Florida Regional Medical Center in Gainesville. Later that year, it signed an agreement to sell Garden Park Medical Center to Singing River Health System.
In 2021, HCA sold Redmond Regional Medical Center to AdventHealth for $635M, and four other Georgia hospitals to Piedmont Healthcare for $950 million. They also announced the acquisition of Meadows Regional Medical Center.
United Kingdom
HCA International, the UK arm of Hospital Corporation of America, "caters for around half of all private patients in London." The main hospital sites within the United Kingdom it operates include:
It opened urgent care walk-in centres at London Bridge Hospital and the Portland Hospital in March 2018. It claims that patients, on average, wait just seven minutes to see a nurse and 17 minutes to see a doctor. In February 2022, outsourced cleaning staff at London Bridge Hospital reported a lack of PPE, no access to sick pay, a lack of training and no prior warning about which rooms may be contaminated with the virus through the COVID-19 pandemic.
The Princess Grace Hospital specializes in breast cancer and surgery, aided by Kefah Mokbel and Nick Perry who, in 2005, founded The London Breast Institute.
The company opened The Harborne Hospital, a newly built private hospital located close to the Queen Elizabeth Hospital, Birmingham, in February 2024.
Significant areas of operation
Medical education
In recent years, HCA Healthcare has become a significant provider of clinical and medical education. It is the largest sponsor of graduate medical education programs in the U.S., with 56 teaching hospitals in 14 states, primarily in regions with a deficit of physician training programs. The company includes Research College of Nursing and Mercy School of Nursing, and has several advanced nursing simulation training centers. In early 2020, it completed the purchase of a majority stake in Galen College of Nursing, which operates 21 campuses in 12 states, offering Bachelor of Science and Associate of Science nursing degrees.
Controversies
Medicare billing practices lawsuit
In 1993, lawsuits were filed against HCA by former employees who alleged that the company had engaged in questionable Medicare billing practices. In 1997, with a federal investigation by the FBI, the IRS and the Department of Health and Human Services in its early stages, the Columbia/HCA board of directors forced Rick Scott to resign as chairman and CEO amid growing evidence that the company "had kept two sets of books, one to show the government and one with actual expenses listed." Thomas Frist, a co-founder of HCA and brother of U.S. Senator Bill Frist, returned to the company as CEO in 1997 and called on longtime friend and colleague Jack O. Bovender Jr. to help him turn the company around.
The federal probe culminated in 2003 with "the government receiving a total of over $2 billion in criminal fines and civil penalties for systematically defrauding federal health care programs." Columbia/HCA pleaded guilty to 14 felonies and admitted to systematically overcharging the government. The federal probe has been referred to as the longest and costliest investigation for health-care fraud in U.S. history.
2005 insider trading suit
In July 2005, U.S. Senator Bill Frist sold all of his HCA shares, which were held in a blind trust, two weeks before disappointing earnings sent the stock on a 9-point plunge. At the time, Frist was considering a run for president and said that he had sold his shares to avoid the appearance of a conflict of interest. When the company disclosed that other executives had also sold their shares during that same time, shareholders alleged that the company had made false claims about its profits to drive up the price, which then fell when the company reported disappointing financial results. Eleven of HCA's senior officers were sued for accounting fraud and insider trading. HCA settled the lawsuit in August 2007, agreeing to pay $20 million to the shareholders but admitting no wrongdoing, and no charges were brought.
COVID-19 PPE
During the COVID-19 pandemic in the United States, HCA hospital nurses and other workers spoke out about the lack of PPE. In April 2020, there was an outcry against HCA following the deaths of two nurses Celia Yap-Banago and Rosa Luna who worked at HCA hospitals in Kansas City and California and had contracted coronavirus, despite the alarm having been raised about the lack of PPE at work.
Mission Hospital Acquisition Complaints
On December 14, 2023, the North Carolina Attorney General sued HCA for violating the terms of an agreement that allowed HCA to purchase Mission Health.
On February 13, 2024, HCA Healthcare denied the allegations and asked a judge to dismiss the lawsuit by the Attorney General, and in return the hospital network filed a counterclaim against the Attorney General.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | HCA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | 14.35Y avg ≈13.8 | ≈13.8 | 16.5 | Undervalued | |
| P/S (TTM) | 1.25Y avg ≈1.2 | ≈1.2 | 1.2 | Fair value | |
| P/B (MRQ) | -14.05Y avg ≈-39.2 | ≈-39.2 | · | · | |
| EV / EBITDA | 38.75Y avg ≈37.3 | ≈37.3 | 18.9 | Overvalued | |
| Price / FCF (TTM) | 15.55Y avg ≈14.6 | ≈14.6 | · | · | |
| Price / Cash Flow (TTM) | 8.45Y avg ≈7.9 | ≈7.9 | 9.1 | Undervalued | |
| EV / Revenue | 1.85Y avg ≈1.8 | ≈1.8 | · | · | |
| EV / FCF | 17.75Y avg ≈21.8 | ≈21.8 | · | · | |
| PEG Ratio | ≈0.7 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | HCA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| EBITDA Margin | 4.7%5Y avg ≈4.8% | ≈4.8% | 11.1% | Weak | |
| Pretax Margin (TTM) | 12.7%5Y avg ≈13.6% | ≈13.6% | 10.3% | Top tier | |
| Net Profit Margin (TTM) | 8.8%5Y avg ≈9.3% | ≈9.3% | 7.3% | In line | |
| ROA (TTM) | 11.1%5Y avg ≈11.2% | ≈11.2% | 6.5% | Top tier | |
| ROE (TTM) | -124.0%5Y avg ≈-963.7% | ≈-963.7% | 19.1% | Weak |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | HCA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | -6.55Y avg ≈-19.5 | ≈-19.5 | 0.1 | Low debt | |
| Current Ratio (MRQ) | 1.05Y avg ≈1.2 | ≈1.2 | 1.2 | Low liquidity | |
| Quick Ratio | 0.75Y avg ≈0.9 | ≈0.9 | 0.9 | Low liquidity | |
| Long-Term Debt / Equity (MRQ) | -6.55Y avg ≈-18.7 | ≈-18.7 | 0.1 | Low debt |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | HCA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 7.1%5Y avg ≈8.0% | ≈8.0% | · | · | |
| Revenue CAGR 3Y | 7.9%5Y avg ≈7.4% | ≈7.4% | · | · | |
| Revenue CAGR 5Y | 8.0% | · | · | · | |
| EPS YoY | 28.8%5Y avg ≈25.6% | ≈25.6% | · | · | |
| Net Income YoY | 17.8%5Y avg ≈17.4% | ≈17.4% | · | · | |
| EPS CAGR 3Y | 13.9%5Y avg ≈11.8% | ≈11.8% | · | · | |
| EPS CAGR 5Y | 21.0% | · | · | · | |
| Net Income CAGR 3Y | 6.3%5Y avg ≈4.0% | ≈4.0% | · | · | |
| Net Income CAGR 5Y | 12.6% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | HCA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 1.35Y avg ≈1.2 | ≈1.2 | 0.8 | Top tier | |
| Receivables Turnover | 7.05Y avg ≈7.1 | ≈7.1 | 8.3 | Weak | |
| Revenue / Employee | ≈$328.7K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Dividends Yield, payout ratio, dividend history, 5Y CAGR
| Ex-date | Amount | Currency | Yield |
|---|---|---|---|
| Sep 16, 2026 | $0.78 | USD | ≈0.71% |
| Jun 16, 2026 | $0.78 | USD | ≈0.76% |
| Mar 17, 2026 | $0.78 | USD | ≈0.58% |
| Dec 15, 2025 | $0.72 | USD | ≈0.60% |
| Sep 16, 2025 | $0.72 | USD | ≈0.71% |
| Jun 16, 2025 | $0.72 | USD | ≈0.75% |
| Mar 17, 2025 | $0.72 | USD | ≈0.82% |
| Dec 13, 2024 | $0.66 | USD | ≈0.84% |
| Sep 16, 2024 | $0.66 | USD | ≈0.64% |
| Jun 14, 2024 | $0.66 | USD | ≈0.75% |
| Mar 14, 2024 | $0.66 | USD | ≈0.76% |
| Dec 13, 2023 | $0.60 | USD | ≈0.89% |
| Sep 14, 2023 | $0.60 | USD | ≈0.90% |
| Jun 15, 2023 | $0.60 | USD | ≈0.81% |
| Mar 16, 2023 | $0.60 | USD | ≈0.90% |
| Dec 13, 2022 | $0.56 | USD | ≈0.92% |
| Sep 15, 2022 | $0.56 | USD | ≈1.0% |
| Jun 15, 2022 | $0.56 | USD | ≈1.1% |
| Mar 16, 2022 | $0.56 | USD | ≈0.75% |
| Dec 13, 2021 | $0.48 | USD | ≈0.90% |
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Jul 23, 2026 | $7.62 | $7.54 | 1.0% |
| March 31, 2026 | $7.15 | $7.21 | -0.85% | |
| Dec. 31, 2025 | $8.14 | $7.53 | 8.0% | |
| Sept. 30, 2025 | $6.96 | $5.77 | 20.6% | |
| June 30, 2025 | $6.83 | $6.31 | 8.2% | |
| March 31, 2025 | $6.45 | $5.84 | 10.5% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| SG&A Expense | $548M | $421M | $353M | $307M | $337M | $416M | $370M | $344M | $340M | $343M | |
| Operating Expenses | $65.77B | $62.08B | $57.26B | $51.65B | $48.92B | $46.10B | $46.09B | $41.34B | $39.23B | $36.68B | |
| Interest Expense | $2.25B | $2.06B | $1.94B | $1.74B | $1.57B | $1.58B | $1.82B | $1.75B | $1.69B | $1.71B | |
| Pretax Income | $9.83B | $8.52B | $7.71B | $8.58B | $9.83B | $5.43B | $5.24B | $5.33B | $4.38B | $4.81B | |
| Income Tax | $2.05B | $1.87B | $1.61B | $1.75B | $2.11B | $1.04B | $1.10B | $946M | $1.64B | $1.38B | |
| Net Income | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| EPS (Basic) | $28.70 | $22.27 | $19.25 | $19.43 | $21.52 | $11.10 | $10.27 | $10.90 | $6.12 | $7.53 | |
| EPS (Diluted) | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 | $10.93 | $10.07 | $10.66 | $5.95 | $7.30 | |
| Shares (Basic) | 236,413,000 | 258,603,000 | 272,404,000 | 290,348,000 | 323,315,000 | 338,274,000 | 341,210,000 | 347,297,000 | 362,305,000 | 383,591,000 | |
| Shares (Diluted) | 239,495,000 | 261,806,000 | 276,412,000 | 294,666,000 | 328,752,000 | 343,605,000 | 348,226,000 | 355,303,000 | 372,221,000 | 395,851,000 | |
| EBITDA | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.04B | $1.93B | $935M | $908M | $1.45B | $1.79B | $621M | $502M | $732M | $646M | |
| Short-term Investments | · | · | · | · | · | $116M | $147M | $47M | $54M | $49M | |
| Receivables | $10.87B | $10.75B | $9.96B | $8.89B | $8.10B | $7.05B | $7.38B | $6.79B | $6.50B | $5.83B | |
| Inventory | $1.65B | $1.74B | $2.02B | $2.07B | $1.99B | $2.02B | $1.85B | $1.73B | $1.57B | $1.50B | |
| Other Current Assets | $2.22B | $1.99B | $2.01B | $1.78B | $2.01B | $1.46B | $1.35B | $1.19B | $1.17B | $1.11B | |
| Current Assets | $15.78B | $16.41B | $14.93B | $13.64B | $13.54B | $12.33B | $11.20B | $10.21B | $9.98B | $9.09B | |
| PP&E (Net) | $31.14B | $29.41B | $27.71B | $25.57B | $24.06B | $23.20B | $22.71B | $19.76B | $17.89B | $16.35B | |
| PP&E (Gross) | $66.28B | $62.51B | $58.55B | $54.76B | $51.35B | $49.32B | $47.23B | $42.97B | $40.08B | $37.05B | |
| Accum. Depreciation | $35.13B | $33.10B | $30.83B | $29.18B | $27.29B | $26.12B | $24.52B | $23.21B | $22.19B | $20.70B | |
| Other Non-current Assets | $255M | $230M | $184M | $298M | $598M | $546M | $480M | $690M | $710M | $1.07B | |
| Total Assets | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Accounts Payable | $4.66B | $4.28B | $4.23B | $4.24B | $4.11B | $3.54B | $2.90B | $2.58B | $2.61B | $2.32B | |
| Current Liabilities | $16.35B | $15.18B | $12.65B | $9.90B | $9.58B | $8.70B | $7.76B | $7.57B | $6.16B | $5.83B | |
| Capital Leases | $1.85B | $1.86B | $1.90B | $1.75B | $1.75B | $1.67B | $1.50B | · | · | · | |
| Total Liabilities | · | · | · | · | · | · | $45.62B | $42.12B | $41.59B | $39.39B | |
| Long-term Debt | $44.28B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Total Debt | $41.60B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Retained Earnings | $-5.72B | $-2.12B | $-1.35B | $-2.28B | $-532M | $777M | $-2.35B | $-4.57B | $-6.53B | $-6.97B | |
| AOCI | $-305M | $-387M | $-425M | $-490M | $-404M | $-502M | $-460M | $-381M | $-278M | $-338M | |
| Stockholders' Equity | $-6.03B | $-2.50B | $-1.77B | $-2.77B | $-933M | $572M | $-2.81B | $-4.95B | $-6.81B | $-7.30B | |
| Liabilities + Equity | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Shares Outstanding | 224,605,100 | 249,981,400 | 265,537,300 | 277,378,300 | 305,476,800 | 339,425,600 | 338,445,600 | 342,895,200 | 350,091,600 | 370,535,900 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B | |
| Stock-based Comp | $401M | $360M | $262M | $341M | $440M | $362M | $347M | $268M | $270M | $251M | |
| Amort. of Intangibles | $12M | $16M | $20M | $44M | $25M | $26M | · | · | · | · | |
| Other Non-cash | $1.93B | $1.08B | $850M | $-431M | $-1.29B | $2.40B | $1.07B | $461M | $-3.53B | $-2.67B | |
| Operating Cash Flow | $12.64B | $10.51B | $9.43B | $8.52B | $8.96B | $9.23B | $7.60B | $6.76B | $5.43B | $5.65B | |
| CapEx | $4.94B | $4.88B | $4.74B | $4.39B | $3.58B | $2.83B | $4.16B | $3.57B | $3.02B | $2.76B | |
| Investing Cash Flow | $-4.99B | $-4.93B | $-5.32B | $-3.39B | $-2.64B | $-3.39B | $-5.72B | $-3.90B | $-4.28B | $-3.24B | |
| Debt Issued | $8.47B | $7.50B | $3.22B | $6.00B | $4.34B | $2.70B | $6.45B | $2.00B | $1.50B | $5.40B | |
| Net Debt Issued | $1.08B | $5.08B | $2.31B | $3.17B | $475M | $-737M | $1.13B | $296M | $749M | $925M | |
| Stock Repurchased | $10.07B | $6.04B | $3.81B | $7.00B | $8.21B | $441M | $1.03B | $1.53B | $2.05B | $2.75B | |
| Net Stock Activity | $-10.07B | $-6.04B | $-3.81B | $-7.00B | $-8.21B | $-441M | $-1.03B | $-1.53B | $-2.05B | $-2.75B | |
| Dividends Paid | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · | |
| Financing Cash Flow | $-8.55B | $-4.58B | $-4.09B | $-5.66B | $-6.66B | $-4.68B | $-1.77B | $-3.08B | $-1.06B | $-2.51B | |
| Net Change in Cash | $-893M | $998M | $27M | $-543M | $-342M | $1.17B | $119M | $-230M | $86M | $-95M | |
| Taxes Paid | $1.74B | $1.84B | $1.39B | $1.18B | $2.18B | $1.00B | $849M | $872M | $1.21B | $1.25B | |
| Free Cash Flow | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B | $6.40B | $3.44B | $3.19B | $2.41B | $2.89B | |
| Levered FCF | $5.91B | $4.03B | $3.16B | $2.74B | $4.15B | $5.12B | $2.00B | $1.74B | $1.35B | $1.68B |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 9.0% | 8.2% | 8.1% | 9.4% | 11.8% | 7.3% | 6.8% | 8.1% | · | · | |
| Pretax Margin | 13.0% | 12.1% | 11.9% | 14.2% | 16.7% | 10.5% | 10.2% | 11.4% | · | · | |
| EBITDA Margin | 4.7% | 4.7% | 4.7% | 4.9% | 4.9% | 5.3% | 5.1% | 4.9% | · | · | |
| ROA | 11.3% | 10.0% | 9.7% | 10.9% | 14.2% | 8.1% | 8.3% | 10.0% | 6.3% | 8.7% | |
| ROE | -159.1% | -269.6% | -230.9% | -305.0% | -3853.7% | -335.8% | -90.4% | -64.4% | -31.4% | -38.8% |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 | 1.4 | 1.4 | 1.3 | 1.6 | 1.6 | |
| Quick Ratio | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 | 1.0 | 1.1 | 1.0 | 1.2 | 1.1 | |
| Debt / Equity | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 | 54.2 | -12.0 | -6.6 | -4.9 | -4.3 | |
| LT Debt / Equity | -6.9 | -15.3 | -21.0 | -13.6 | -36.8 | 53.8 | -12.0 | -6.5 | -4.8 | -4.3 |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.3 | 1.2 | 1.2 | 1.2 | 1.2 | 1.1 | 1.2 | 1.2 | · | · | |
| Receivables Turnover | 7.0 | 6.8 | 6.9 | 7.1 | 7.8 | 7.1 | 7.2 | 7.0 | · | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-26.83 | $-10.00 | $-6.68 | $-9.98 | $-3.05 | $1.69 | $-8.30 | $-14.44 | $-19.44 | $-19.71 | |
| Revenue / Share | $315.66 | $269.68 | $235.04 | $204.41 | $178.71 | $149.98 | $147.42 | $131.37 | · | · | |
| Cash Flow / Share | $52.76 | $40.16 | $34.12 | $28.92 | $27.25 | $26.87 | $21.83 | $19.03 | $14.58 | $14.28 | |
| Cash / Share | $4.63 | $7.73 | $3.52 | $3.27 | $4.75 | $5.28 | $1.83 | $1.46 | $2.09 | $1.74 | |
| Dividend / Share | $2.88 | $2.64 | $2.40 | $2.24 | $1.92 | $0.43 | $1.60 | $1.40 | · | · | |
| EPS (TTM) | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 | $10.93 | $10.07 | $10.66 | $5.95 | $7.30 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 7.1% | 8.7% | 7.9% | 2.5% | 14.0% | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.9% | 6.3% | 8.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 8.0% | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 28.8% | 16.0% | -0.94% | -9.5% | 93.6% | · | · | · | · | · | |
| EPS CAGR 3Y | 13.9% | 1.3% | 20.2% | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 21.0% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 17.8% | 9.9% | -7.1% | -18.9% | 85.3% | · | · | · | · | · | |
| Net Income CAGR 3Y | 6.3% | -6.1% | 11.8% | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 12.6% | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 34.7% | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| Net Income TTM | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| Market Cap | $104.86B | $75.03B | $71.88B | $66.56B | $78.48B | $55.82B | $50.03B | $42.67B | $30.75B | $27.43B | |
| Enterprise Value | $145.42B | $116.13B | $110.53B | $103.74B | $111.61B | $84.92B | $82.98B | $74.95B | $63.02B | $58.11B | |
| P/E | 16.5 | 13.6 | 14.3 | 12.5 | 12.1 | 15.0 | 14.7 | 11.7 | 14.8 | 10.1 | |
| P/S | 1.4 | 1.1 | 1.1 | 1.1 | 1.3 | 1.1 | 1.0 | 0.9 | 0.7 | 0.7 | |
| P/B | -17.4 | -30.0 | -40.5 | -24.1 | -84.1 | 97.6 | -17.8 | -8.6 | -4.5 | -3.8 | |
| P / Tangible Book | · | · | · | · | · | 97.6 | · | · | · | · | |
| P / Cash Flow | 8.3 | 7.1 | 7.6 | 7.8 | 8.8 | 6.0 | 6.6 | 6.3 | 5.7 | 4.9 | |
| P / FCF | 13.6 | 13.3 | 15.3 | 16.1 | 14.6 | 8.7 | 14.5 | 13.4 | 12.8 | 9.5 | |
| EV / EBITDA | 41.3 | 35.1 | 35.9 | 34.9 | 39.1 | 31.2 | 32.0 | 32.9 | 29.6 | 29.6 | |
| EV / FCF | 18.9 | 20.6 | 23.6 | 25.1 | 20.7 | 13.3 | 24.1 | 23.5 | 26.1 | 20.1 | |
| EV / Revenue | 1.9 | 1.6 | 1.7 | 1.7 | 1.9 | 1.6 | 1.6 | 1.6 | 1.4 | 1.4 | |
| Dividend Yield | 0.65% | 0.92% | 0.92% | 0.98% | 0.80% | 0.27% | 1.1% | 1.1% | 0.00% | · | |
| Earnings Yield | 6.1% | 7.3% | 7.0% | 8.0% | 8.2% | 6.7% | 6.8% | 8.6% | 6.8% | 9.9% | |
| Payout Ratio | 10.0% | 12.0% | 12.6% | 11.6% | 9.0% | 4.1% | 15.7% | 12.9% | · | · | |
| Annual Payout | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.23B | $19.11B | $19.51B | $19.16B | $18.61B | $18.32B | $18.29B | $17.49B | $17.49B | $17.34B | $17.30B | $16.21B | $15.86B | $15.59B | $15.50B | $14.97B | |
| SG&A Expense | $148M | $133M | $153M | $139M | $130M | $126M | $120M | $111M | $100M | $90M | $108M | $89M | $82M | $74M | $79M | $74M | |
| Operating Expenses | $17.74B | $16.82B | $16.84B | $16.74B | $16.19B | $15.99B | $16.15B | $15.58B | $15.26B | $15.09B | $14.96B | $14.58B | $14.05B | $13.67B | $12.20B | $13.27B | |
| Interest Expense | $599M | $584M | $572M | $561M | $568M | $547M | $528M | $515M | $506M | $512M | $491M | $483M | $485M | $479M | $453M | $446M | |
| Pretax Income | $2.49B | $2.29B | $2.67B | $2.42B | $2.42B | $2.33B | $2.13B | $1.91B | $2.24B | $2.25B | $2.35B | $1.63B | $1.81B | $1.92B | $3.30B | $1.70B | |
| Income Tax | $564M | $430M | $509M | $515M | $524M | $502M | $447M | $424M | $550M | $445M | $484M | $355M | $397M | $379M | $656M | $360M | |
| Net Income | $1.70B | $1.62B | $1.88B | $1.64B | $1.65B | $1.61B | $1.44B | $1.27B | $1.46B | $1.59B | $1.61B | $1.08B | $1.19B | $1.36B | $2.08B | $1.13B | |
| EPS (Basic) | $7.70 | $7.25 | $8.22 | $7.05 | $6.91 | $6.52 | $5.72 | $4.94 | $5.60 | $6.01 | $6.00 | $3.98 | $4.35 | $4.92 | $7.30 | $3.97 | |
| EPS (Diluted) | $7.62 | $7.15 | $8.09 | $6.96 | $6.83 | $6.45 | $5.66 | $4.88 | $5.53 | $5.93 | $5.92 | $3.91 | $4.29 | $4.85 | $7.20 | $3.91 | |
| Shares (Basic) | 220,538,000 | 223,588,000 | · | 232,891,000 | 239,173,000 | 246,936,000 | · | 256,763,000 | 261,156,000 | 264,435,000 | · | 271,173,000 | 274,494,000 | 276,910,000 | · | 285,958,000 | |
| Shares (Diluted) | 222,828,000 | 226,652,000 | · | 236,181,000 | 241,911,000 | 249,440,000 | · | 259,917,000 | 264,071,000 | 268,016,000 | · | 275,424,000 | 278,198,000 | 280,961,000 | · | 289,852,000 | |
| EBITDA | $944M | $930M | · | $889M | $863M | $860M | · | $842M | $819M | $795M | · | $769M | $763M | $756M | · | $749M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.01B | $940M | $1.04B | $997M | $939M | $1.06B | $1.93B | $2.89B | $831M | $1.28B | · | $891M | $862M | $842M | · | $999M | |
| Receivables | $12.28B | $11.32B | $10.87B | $10.43B | $10.46B | $11.09B | $10.75B | $9.91B | $10.24B | $10.04B | · | $9.18B | $8.71B | $8.66B | · | $8.55B | |
| Inventory | $1.66B | $1.68B | $1.65B | $1.73B | $1.79B | $1.79B | $1.74B | $1.78B | $1.80B | $1.90B | · | $2.03B | $2.05B | $2.08B | · | $2.01B | |
| Other Current Assets | $2.23B | $2.11B | $2.22B | $2.13B | $2.37B | $2.32B | $1.99B | $2.08B | $2.30B | $2.05B | · | $2.19B | $2.26B | $1.96B | · | $1.92B | |
| Current Assets | $17.19B | $16.05B | $15.78B | $15.29B | $15.56B | $16.26B | $16.41B | $16.66B | $15.17B | $15.28B | · | $14.29B | $13.89B | $13.54B | · | $13.48B | |
| PP&E (Net) | $31.82B | $31.47B | $31.14B | $30.57B | $30.12B | $29.74B | $29.41B | $29.05B | $28.64B | $28.10B | · | $27.12B | $26.64B | $26.05B | · | $24.98B | |
| PP&E (Gross) | $68.41B | $67.36B | $66.28B | $65.49B | $64.39B | $63.68B | $62.51B | $61.75B | $60.62B | $59.44B | · | $57.77B | $56.67B | $55.46B | · | $53.73B | |
| Accum. Depreciation | $36.59B | $35.89B | $35.13B | $34.92B | $34.27B | $33.94B | $33.10B | $32.70B | $31.99B | $31.34B | · | $30.66B | $30.02B | $29.41B | · | $28.75B | |
| Other Non-current Assets | $258M | $326M | $255M | $277M | $236M | $226M | $230M | $309M | $240M | $199M | · | $200M | $196M | $319M | · | $461M | |
| Total Assets | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | $56.21B | $54.59B | $53.59B | $52.71B | $52.44B | $51.48B | |
| Accounts Payable | $4.75B | $4.81B | $4.66B | $4.55B | $4.25B | $4.49B | $4.28B | $4.24B | $4.03B | $4.74B | · | $4.14B | $3.82B | $3.77B | · | $4.16B | |
| Current Liabilities | $17.31B | $19.26B | $16.35B | $17.90B | $15.94B | $13.63B | $15.18B | $14.90B | $14.30B | $13.14B | · | $12.41B | $11.54B | $11.03B | · | $9.78B | |
| Capital Leases | $1.83B | $1.82B | $1.85B | $1.84B | $1.88B | $1.86B | $1.86B | $1.92B | $1.89B | $1.91B | · | $1.78B | $1.81B | $1.72B | · | $1.76B | |
| Long-term Debt | $45.83B | $44.37B | $44.28B | $42.60B | $42.70B | $44.58B | $43.03B | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Total Debt | $43.45B | $39.49B | · | $38.40B | $39.38B | $44.58B | · | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Retained Earnings | $-6.31B | $-5.98B | $-5.72B | $-5.02B | $-4.09B | $-3.16B | $-2.12B | $-1.81B | $-1.17B | $-1.19B | · | $-1.99B | $-1.85B | $-2.03B | · | $-2.78B | |
| AOCI | $-334M | $-327M | $-305M | $-317M | $-309M | $-357M | $-387M | $-378M | $-433M | $-433M | $-425M | $-491M | $-456M | $-470M | $-490M | $-592M | |
| Stockholders' Equity | $-6.64B | $-6.30B | $-6.03B | $-5.33B | $-4.39B | $-3.52B | $-2.50B | $-2.18B | $-1.60B | $-1.61B | · | $-2.48B | $-2.30B | $-2.50B | · | $-3.37B | |
| Liabilities + Equity | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | · | $54.59B | $53.59B | $52.71B | · | $51.48B | |
| Shares Outstanding | 217,963,300 | 222,530,900 | 224,605,100 | 229,845,100 | 236,143,900 | 242,955,400 | 249,981,400 | 254,517,700 | 259,237,600 | 263,215,800 | · | 268,967,300 | 272,931,700 | 275,939,900 | · | 283,903,500 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $944M | $930M | $911M | $889M | $863M | $860M | $856M | $842M | $819M | $795M | $789M | $769M | $763M | $756M | $750M | $749M | |
| Stock-based Comp | $85M | $86M | $100M | $104M | $99M | $98M | $85M | $76M | $112M | $87M | $57M | $72M | $56M | $77M | $83M | $87M | |
| Other Non-cash | · | $-622M | · | · | · | $-917M | · | · | · | $-4M | · | · | · | $-393M | · | · | |
| Operating Cash Flow | $2.33B | $2.01B | $2.36B | $4.42B | $4.21B | $1.65B | $2.56B | $3.52B | $1.97B | $2.47B | $2.67B | $2.48B | $2.48B | $1.80B | $2.53B | $3.02B | |
| CapEx | $1.23B | $1.12B | $1.49B | $1.29B | $1.18B | $991M | $1.28B | $1.19B | $1.28B | $1.12B | $1.16B | $1.15B | $1.24B | $1.20B | $1.32B | $1.13B | |
| Investing Cash Flow | $-1.56B | $-1.28B | $-1.32B | $-1.39B | $-1.25B | $-1.03B | $-1.35B | $-1.35B | $-1.33B | $-903M | $-1.60B | $-1.31B | $-1.26B | $-1.15B | $-793M | $-546M | |
| Debt Issued | $2.99B | $0 | $3.24B | $0 | $0 | $5.23B | $0 | $3.01B | $0 | $4.48B | $4M | $2M | $3.22B | $0 | $21M | $10M | |
| Net Debt Issued | · | $-58M | · | · | · | $1.34B | · | · | · | $2.42B | · | · | · | $-550M | · | · | |
| Stock Repurchased | $2.06B | $1.57B | $2.56B | $2.50B | $2.50B | $2.51B | $1.70B | $1.79B | $1.37B | $1.18B | $910M | $1.14B | $915M | $846M | $1.52B | $698M | |
| Net Stock Activity | · | $-1.57B | · | · | · | $-2.51B | · | · | · | $-1.18B | · | · | · | $-846M | · | · | |
| Dividends Paid | $171M | $183M | $162M | $166M | $171M | $180M | $165M | $169M | $171M | $185M | $160M | $162M | $164M | $175M | $156M | $160M | |
| Financing Cash Flow | $-704M | $-830M | $-999M | $-2.97B | $-3.09B | $-1.50B | $-2.16B | $-110M | $-1.09B | $-1.22B | $-1.04B | $-1.13B | $-1.20B | $-725M | $-1.84B | $-2.32B | |
| Net Change in Cash | $73M | $-100M | $43M | $58M | $-121M | $-873M | $-955M | $2.06B | $-453M | $349M | $44M | $29M | $20M | $-66M | $-91M | $141M | |
| Taxes Paid | $730M | $-5M | $1.51B | $81M | $136M | $10M | $358M | $487M | $998M | $1M | $316M | $297M | $766M | $7M | $244M | $322M | |
| Free Cash Flow | · | $895M | · | · | · | $660M | · | · | · | $1.35B | · | · | · | $606M | · | · | |
| Levered FCF | · | $421M | · | · | · | $231M | · | · | · | $940M | · | · | · | $221M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 8.4% | 8.5% | · | 8.6% | 8.9% | 8.8% | · | 7.3% | 8.3% | 9.2% | · | 6.7% | 7.5% | 8.7% | · | 7.6% | |
| Pretax Margin | 12.3% | 12.0% | · | 12.6% | 13.0% | 12.7% | · | 10.9% | 12.8% | 13.0% | · | 10.1% | 11.4% | 12.3% | · | 11.4% | |
| EBITDA Margin | 4.7% | 4.9% | · | 4.6% | 4.6% | 4.7% | · | 4.8% | 4.7% | 4.6% | · | 4.7% | 4.8% | 4.9% | · | 5.0% | |
| ROA | 2.8% | 2.7% | · | 2.8% | 2.8% | 2.8% | · | 2.2% | 2.6% | 2.9% | · | 2.0% | 2.3% | 2.6% | · | 2.2% | |
| ROE | -30.8% | -33.0% | · | -43.7% | -55.2% | -62.7% | · | -54.5% | -74.9% | -77.4% | · | -36.9% | -39.9% | -60.2% | · | -55.8% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 0.8 | · | 0.9 | 1.0 | 1.2 | · | 1.1 | 1.1 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.4 | |
| Quick Ratio | 0.8 | 0.6 | · | 0.6 | 0.7 | 0.9 | · | 0.9 | 0.8 | 0.9 | · | 0.8 | 0.8 | 0.9 | · | 1.0 | |
| Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -12.7 | · | -19.7 | -25.6 | -24.9 | · | -15.9 | -16.9 | -15.6 | · | -11.2 | |
| LT Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -11.7 | · | -17.5 | -22.7 | -23.0 | · | -14.9 | -15.9 | -14.6 | · | -11.1 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | |
| Receivables Turnover | 1.8 | 1.7 | · | 1.9 | 1.8 | 1.7 | · | 1.8 | 1.8 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-30.47 | $-28.32 | · | $-23.21 | $-18.61 | $-14.48 | · | $-8.57 | $-6.17 | $-6.14 | · | $-9.21 | $-8.44 | $-9.04 | · | $-11.87 | |
| Revenue / Share | $90.79 | $84.31 | · | $81.13 | $76.91 | $73.45 | · | $67.28 | $66.24 | $64.69 | · | $58.87 | $57.01 | $55.49 | · | $51.65 | |
| Cash Flow / Share | · | $8.89 | · | · | · | $6.62 | · | · | · | $9.21 | · | · | · | $6.42 | · | · | |
| Cash / Share | $4.65 | $4.22 | · | $4.34 | $3.98 | $4.36 | · | $11.35 | $3.21 | $4.88 | · | $3.31 | $3.16 | $3.05 | · | $3.52 | |
| Dividend / Share | $0.78 | $0.78 | $0.72 | $0.72 | $0.72 | $0.72 | $0.66 | $0.66 | $0.66 | $0.66 | $0.60 | $0.60 | $0.60 | $0.60 | $0.56 | $0.56 | |
| EPS (TTM) | $29.82 | $29.03 | · | $25.90 | $23.82 | $22.52 | · | $22.26 | $21.29 | $20.05 | · | $20.25 | $20.25 | $19.86 | · | $17.61 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $78.01B | $76.39B | · | $74.37B | $72.70B | $71.58B | · | $69.62B | $68.35B | $66.72B | · | $63.16B | $61.92B | $60.88B | · | $59.80B | |
| Net Income TTM | $6.84B | $6.79B | · | $6.34B | $5.97B | $5.78B | · | $5.93B | $5.74B | $5.47B | · | $5.72B | $5.77B | $5.73B | · | $5.38B | |
| Market Cap | $84.98B | $105.31B | · | $97.96B | $90.47B | $83.95B | · | $103.44B | $83.29B | $87.79B | · | $66.16B | $82.83B | $72.76B | · | $52.18B | |
| Enterprise Value | $127.42B | $143.86B | · | $135.36B | $128.91B | $127.47B | · | $143.52B | $123.34B | $126.70B | · | $104.62B | $120.90B | $110.77B | · | $88.89B | |
| P/E | 13.1 | 16.3 | · | 16.5 | 16.1 | 15.3 | · | 18.3 | 15.1 | 16.6 | · | 12.1 | 15.0 | 13.3 | · | 10.4 | |
| P/S | 1.1 | 1.4 | · | 1.3 | 1.2 | 1.2 | · | 1.5 | 1.2 | 1.3 | · | 1.0 | 1.3 | 1.2 | · | 0.9 | |
| P/B | -12.8 | -16.7 | · | -18.4 | -20.6 | -23.9 | · | -47.4 | -52.1 | -54.4 | · | -26.7 | -36.0 | -29.2 | · | -15.5 | |
| P / Cash Flow | · | 52.3 | · | · | · | 50.8 | · | · | · | 35.6 | · | · | · | 40.4 | · | · | |
| EV / Revenue | 1.6 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.1 | 1.8 | 1.9 | · | 1.7 | 2.0 | 1.8 | · | 1.5 | |
| Dividend Yield | 0.80% | 0.65% | · | 0.70% | 0.76% | 0.82% | · | 0.66% | 0.81% | 0.76% | · | 0.99% | 0.79% | 0.89% | · | 1.2% | |
| Earnings Yield | 7.6% | 6.1% | · | 6.1% | 6.2% | 6.5% | · | 5.5% | 6.6% | 6.0% | · | 8.2% | 6.7% | 7.5% | · | 9.6% | |
| Payout Ratio | · | 11.3% | · | · | · | 11.2% | · | · | · | 11.6% | · | · | · | 12.8% | · | · | |
| Annual Payout | $682M | $682M | · | $682M | $685M | $685M | · | $685M | $678M | $671M | · | $657M | $655M | $651M | · | $645M |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B |
| Net Income | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B |
| Diluted EPS | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debt / Equity | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 |
| Current Ratio | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 |
| Quick Ratio | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B |
Institutional owners (13F) 1,473 filers · $57.3B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 121 (-64 vs prior Q) | 176 (+72 vs prior Q) | 458 (-25 vs prior Q) | 581 (+4 vs prior Q) | -627K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| VANGUARD GROUP INC | $6,870,392,526 | 14,716,173 | 12.00% | Shares |
| BlackRock, Inc. | $5,069,973,824 | 13,003,600 | 8.85% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $3,954,150,533 | 10,141,708 | 6.91% | Shares |
| Sanders Capital, LLC | $3,442,060,818 | 8,828,287 | 6.01% | Shares |
| STATE STREET CORP | $2,912,102,056 | 7,469,035 | 5.09% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $1,835,396,649 | 4,707,473 | 3.21% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $1,423,654,808 | 3,668,008 | 2.49% | Shares |
| First Eagle Investment Management, LLC | $1,284,907,912 | 3,295,565 | 2.24% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1,057,704,509 | 2,712,828 | 1.85% | Shares |
| MORGAN STANLEY | $1,008,556,857 | 2,586,771 | 1.76% | Shares |
| GOLDMAN SACHS GROUP INC | $960,811,481 | 2,464,314 | 1.68% | Shares |
| JPMORGAN CHASE & CO | $896,800,955 | 2,285,832 | 1.57% | Shares |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $861,456,107 | 2,209,485 | 1.50% | Shares |
| NORGES BANK | $836,457,140 | 2,145,367 | 1.46% | Shares |
| Capital World Investors | $770,864,224 | 1,977,121 | 1.35% | Shares |
| Capital International Investors | $747,403,041 | 1,916,947 | 1.31% | Shares |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $709,859,997 | 1,500,000 | 1.24% | Shares |
| NORTHERN TRUST CORP | $666,150,458 | 1,708,560 | 1.16% | Shares |
| FMR LLC | $636,503,475 | 1,632,520 | 1.11% | Shares |
| Invesco Ltd. | $596,390,232 | 1,529,637 | 1.04% | Shares |
| NORDEA INVESTMENT MANAGEMENT AB | $553,702,529 | 1,429,943 | 0.97% | Shares |
| BARCLAYS PLC | $514,349,127 | 1,319,216 | 0.90% | Shares |
| JANUS HENDERSON GROUP PLC | $481,486,890 | 1,017,441 | 0.84% | Shares |
| Crake Asset Management LLP | $449,072,183 | 1,151,792 | 0.78% | Shares |
| Metropolis Capital Ltd | $430,915,307 | 910,564 | 0.75% | Shares |
| Darsana Capital Partners LP | $428,879,000 | 1,100,000 | 0.75% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $414,565,358 | 1,063,288 | 0.72% | Shares |
| Legal & General Group Plc | $410,992,402 | 1,054,124 | 0.72% | Shares |
| FRANKLIN RESOURCES INC | $399,958,688 | 1,025,824 | 0.70% | Shares |
| Life Cycle Investment Partners Ltd | $355,737,196 | 912,404 | 0.62% | Shares |
| Bank of New York Mellon Corp | $350,359,895 | 898,612 | 0.61% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $339,685,814 | 871,235 | 0.59% | Shares |
| ROYAL BANK OF CANADA | $320,194,000 | 821,241 | 0.56% | Shares |
| LYRICAL ASSET MANAGEMENT LP | $255,015,742 | 654,071 | 0.45% | Shares |
| BANK OF AMERICA CORP /DE/ | $238,456,934 | 611,601 | 0.42% | Shares |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $237,236,367 | 608,470 | 0.41% | Shares |
| ROYAL LONDON ASSET MANAGEMENT LTD | $235,649,908 | 604,401 | 0.41% | Shares |
| PRINCIPAL FINANCIAL GROUP INC | $234,827,401 | 602,290 | 0.41% | Shares |
| UBS Group AG | $230,953,291 | 592,355 | 0.40% | Shares |
| National Pension Service | $230,650,346 | 591,578 | 0.40% | Shares |
| Russell Investments Group, Ltd. | $206,832,565 | 530,340 | 0.36% | Shares |
| Nuveen, LLC | $199,595,109 | 511,927 | 0.35% | Shares |
| Gobi Capital LLC | $195,742,325 | 502,045 | 0.34% | Shares |
| Cryder Capital Partners LLP | $194,561,738 | 499,017 | 0.34% | Shares |
| Allianz Asset Management GmbH | $181,127,299 | 464,560 | 0.32% | Shares |
| DEUTSCHE BANK AG\ | $175,985,429 | 451,372 | 0.31% | Shares |
| Swiss National Bank | $172,097,446 | 441,400 | 0.30% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $172,079,393 | 441,313 | 0.30% | Shares |
| AustralianSuper Pty Ltd | $159,635,782 | 409,438 | 0.28% | Shares |
| HSBC HOLDINGS PLC | $158,555,065 | 406,750 | 0.28% | Shares |
Activists & 5%+ owners 4 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Frisco Holding II, Hercules Holding II, Thomas F. Frist, Jr., Thomas F. Frist III, William R. Frist, Patricia F. Elcan | Feb. 10, 2026 | 31.60% | Initial filing | · | SEC |
| Nov. 22, 2006 | · | Initial filing | · | SEC | |
| Merrill Lynch Bank USA | Sept. 11, 2006 | · | Initial filing | · | SEC |
| Frisco, Inc., Frisco Partners, Thomas F. Frist, Jr., Patricia Champion Frist, Patricia Frist Elcan, William Robert Frist, Thomas F. Frist III, Merrill Lynch Professional Clearing Corp., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Merrill Lynch Financial Markets, Inc., Merrill Lynch International, Merrill Lynch & Co., Inc., Merrill Lynch Trust Company, FSB, Citigroup Inc.*, Bank of America Corporation, NB Holdings Corporation, NationsBanc Montgomery Holdings Corporation, Banc of America Securities LLC | Aug. 4, 2006 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 92 insiders · 54 officers · 31 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Samuel N Hazen | CEO | Feb. 10, 2026 F | 64,842 | 0 | 7 | $-21,483,290 |
| O'Boyle Michael P | President & CEO - Parallon | Feb. 26, 2013 A | 21,429 | 0 | 0 | $0 |
| Mike A Marks | EVP and CFO | May 7, 2026 G | 46,576 | 0 | 0 | $0 |
| Bill B Rutherford | CFO and EVP | Feb. 16, 2024 F | 22,251 | 0 | 0 | $0 |
| Russell K Harms | CFO - Central Group | Nov. 17, 2006 D | 0 | 0 | 0 | $0 |
| Robert Samuel Hankins JR | CFO-Outpatient Services Group | Nov. 17, 2006 D | 0 | 0 | 0 | $0 |
| Richard J Shallcross | CFO - Western Group | Nov. 17, 2006 D | 0 | 0 | 0 | $0 |
| Jeffrey T Crudele | CFO-Eastern Division | July 1, 2005 F | 13,865 | 0 | 0 | $0 |
| Erol R Akdamar | Group President | Nov. 12, 2024 M | 6,843 | 0 | 0 | $0 |
| Timothy M Mcmanus | Group President | July 31, 2024 M | 27,008 | 0 | 0 | $0 |
| Richard A Hammett | Group President | Feb. 16, 2024 F | 17,936 | 0 | 0 | $0 |
| Charles J Hall | Group President | Nov. 11, 2022 M | 202,443 | 0 | 0 | $0 |
| Bruce A Moore JR | Group President - Service Line | Nov. 11, 2022 S | 30,807 | 0 | 0 | $0 |
| Paul W Rutledge | Group President | Dec. 31, 2012 A | 335,657 | 0 | 0 | $0 |
| Beverly B Wallace | President - Parallon | Nov. 2, 2011 M | 144,714 | 0 | 0 | $0 |
| Charles Robert Evans | President - Eastern Group | July 26, 2006 A | 62,173 | 0 | 0 | $0 |
| Marilyn B Tavenner | President-Outpatient Svcs Grp | Oct. 27, 2005 A | 26,154 | 0 | 0 | $0 |
| Greg Roth | President-Ambulatory Surgery | Oct. 31, 2004 D | 9,029 | 0 | 0 | $0 |
| Jay Grinney | President-Eastern Group | May 7, 2004 D | 24,177 | 0 | 0 | $0 |
| Jon M Foster | EVP and COO | Feb. 10, 2026 F | 23,062 | 0 | 0 | $0 |
| Michael R Mcalevey | EVP & Chief Legal & Admin Off. | Aug. 26, 2026 J | 0 | 0 | 2 | $-2,747,520 |
| Jennifer Berres | SVP & Chief Human Res. Officer | Feb. 11, 2026 S | 11,993 | 0 | 2 | $-4,126,932 |
| Christopher F. Wyatt | SVP & Controller | Feb. 11, 2026 S | 44,379 | 0 | 1 | $-2,020,000 |
| Erica Rossitto | SVP & Chief Nurse Executive | Feb. 10, 2026 F | 10,407 | 0 | 0 | $0 |
| Michael S. Cuffe | EVP and Chief Clinical Officer | Feb. 10, 2026 F | 32,080 | 0 | 1 | $-747,135 |
| Sammie S Mosier | SVP & Chief Nurse Executive | Feb. 13, 2025 F | 11,113 | 0 | 0 | $0 |
| Kathleen M Whalen | SVP & Chief Ethics Officer | Nov. 14, 2024 S | 9,454 | 0 | 0 | $0 |
| Phillip G Billington | SVP-Internal Audit Services | Nov. 12, 2024 M | 52,702 | 0 | 0 | $0 |
| Joseph A Sowell III | SVP; Chief Development Officer | Aug. 5, 2024 G | 18,526 | 0 | 0 | $0 |
| Deborah M Reiner | SVP - Mktg. & Communications | July 29, 2024 S | 3,510 | 0 | 0 | $0 |
| Kathryn A. Torres | SVP-Payer Contracting & Align. | July 25, 2024 S | 17,755 | 0 | 0 | $0 |
| Jeffrey E. Cohen | SVP-Government Relations | May 9, 2024 S | 5,185 | 0 | 0 | $0 |
| Chad J Wasserman | SVP and CIO | March 18, 2024 M | 1,576 | 0 | 0 | $0 |
| Martin P. Paslick | SVP and CIO | April 12, 2023 M | 24,643 | 0 | 0 | $0 |
| Jane D. Englebright | SVP and Chief Nursing Officer | Nov. 9, 2021 S | 0 | 0 | 0 | $0 |
| Robert A Waterman | SVP & General Counsel | May 5, 2021 S | 50,062 | 0 | 0 | $0 |
| William J Morrow | SVP - Finance and Treasurer | Feb. 18, 2021 F | 5,578 | 0 | 0 | $0 |
| Sandra L. Morgan | SVP-Provider Relations | Feb. 18, 2021 F | 10,122 | 0 | 0 | $0 |
| Victor L Campbell | SVP-Government Affairs | May 1, 2019 A | 194,145 | 0 | 0 | $0 |
| John M Steele | SVP & Chief Human Res. Officer | Feb. 25, 2019 M | 84,157 | 0 | 0 | $0 |
| Milton R Johnson | Chairman | Feb. 25, 2019 M | 881,823 | 0 | 0 | $0 |
| Ravi S. Chari | SVP-Clinical Excellence | Feb. 25, 2018 M | 7,003 | 0 | 0 | $0 |
| Alan R Yuspeh | SVP & Chief Ethics Officer | Feb. 25, 2018 M | 35,546 | 0 | 0 | $0 |
| Joseph N Steakley | SVP-Internal Audit Services | Feb. 25, 2018 M | 65,199 | 0 | 0 | $0 |
| Jana Joustra Davis | SVP - Mktg. & Corp. Affairs | May 23, 2017 M | 26,378 | 0 | 0 | $0 |
| David Gwin Anderson | SVP - Finance | Nov. 7, 2016 M | 110,167 | 0 | 0 | $0 |
| Donald W Stinnett | SVP & Controller | Feb. 25, 2016 A | 51,965 | 0 | 0 | $0 |
| Noel B Williams | SVP and CIO | May 16, 2012 M | 299,030 | 0 | 0 | $0 |
| Jack O Bovender JR | Chairman | Oct. 6, 2009 A | 188,340 | 0 | 0 | $0 |
| Carl V George | SVP - Development | Feb. 27, 2009 M | 13,092 | 0 | 0 | $0 |
| Patricia T Lindler | SVP - Government Programs | Nov. 17, 2006 D | 0 | 0 | 0 | $0 |
| Rosalyn S Elton | SVP-Operations Finance | Nov. 17, 2006 D | 0 | 0 | 0 | $0 |
| Frank M Houser MD | SVP-Quality & Medical Director | July 26, 2006 A | 46,145 | 0 | 0 | $0 |
| James A Fitzgerald JR | SVP-Supply Chain Operations | Jan. 29, 2006 F | 20,674 | 0 | 0 | $0 |
| Andrea B Smith | Director | April 28, 2026 A | 4,666 | 0 | 0 | $0 |
| William R Frist | Director | April 28, 2026 A | 13,740 | 0 | 0 | $0 |
| Wayne Joseph Riley | Director | April 28, 2026 A | 15,029 | 0 | 0 | $0 |
| Hugh F Johnston | Director | April 28, 2026 A | 4,475 | 0 | 0 | $0 |
| Thomas F Frist III | Director | April 28, 2026 A | 15,858 | 0 | 0 | $0 |
| Michael W Michelson | Director | April 28, 2026 A | 12,576 | 0 | 0 | $0 |
| Nancy Ann Deparle | Director | April 28, 2026 A | 21,910 | 0 | 0 | $0 |
| John Chidsey | Director | April 28, 2026 A | 1,305 | 0 | 0 | $0 |
| Robert J Dennis | Director | April 29, 2025 A | 26,601 | 0 | 0 | $0 |
| Meg Crofton | Director | April 29, 2024 A | 6,331 | 0 | 0 | $0 |
| Charles O Holliday JR | Director | April 25, 2022 A | 18,955 | 0 | 0 | $0 |
| Geoffrey G Meyers | Director | May 1, 2019 A | 39,153 | 0 | 0 | $0 |
| John W Rowe | Director | May 1, 2019 A | 30,388 | 0 | 0 | $0 |
| Ann H Lamont | Director | May 2, 2018 A | 17,661 | 0 | 0 | $0 |
| Jay O Light | Director | May 3, 2017 A | 30,953 | 0 | 0 | $0 |
| Stephen G Pagliuca | Director | Dec. 5, 2014 D | 7,612,921 | 0 | 0 | $0 |
| Christopher R Gordon | Director | Nov. 1, 2013 D | 30,003,156 | 0 | 0 | $0 |
| John Connaughton | Director | Nov. 1, 2013 D | 30,003,156 | 0 | 0 | $0 |
| John H Mcarthur | Director | Nov. 17, 2006 D | 0 | 0 | 0 | $0 |
| Kent C Nelson | Director | Nov. 17, 2006 D | 0 | 0 | 0 | $0 |
| Magdalena Averhoff MD | Director | Nov. 17, 2006 D | 0 | 0 | 0 | $0 |
| Glenda A Hatchett | Director | Nov. 17, 2006 D | 0 | 0 | 0 | $0 |
| Frederick W Gluck | Director | Nov. 17, 2006 D | 0 | 0 | 0 | $0 |
| Harold T Shapiro | Director | Nov. 17, 2006 D | 0 | 0 | 0 | $0 |
| Michael C Armstrong | Director | Nov. 17, 2006 D | 0 | 0 | 0 | $0 |
| Martin Feldstein | Director | Nov. 17, 2006 D | 0 | 0 | 0 | $0 |
| Michael T Long | Director | Nov. 17, 2006 D | 0 | 0 | 0 | $0 |
| ROYAL FRANK S | Director | Nov. 17, 2006 D | 0 | 0 | 0 | $0 |
| Patricia F Elcan | 10% owner | Feb. 6, 2026 J | 36,557,141 | 0 | 0 | $0 |
| Frisco Holding II | 10% owner | Feb. 6, 2026 J | 36,557,141 | 0 | 0 | $0 |
| HERCULES HOLDING II, LLC | 10% owner | Feb. 6, 2026 J | 32,282,889 | 0 | 0 | $0 |
| Thomas F Frist JR | 10% owner | Feb. 6, 2026 J | 36,557,141 | 0 | 0 | $0 |
| Patricia C Frist | 10% owner | Feb. 20, 2018 G | 0 | 0 | 0 | $0 |
| KKR PEI GP LTD | 10% owner | April 1, 2014 J | 0 | 0 | 0 | $0 |
| Jonathan B Perlin | · | Aug. 2, 2021 S | 44,348 | 0 | 0 | $0 |
| Juan Vallarino | · | May 9, 2016 M | 61,036 | 0 | 0 | $0 |
| Richard M Bracken | · | Dec. 31, 2014 F | 82,499 | 0 | 0 | $0 |
| BANK OF AMERICA CORP /DE/ | · | Nov. 6, 2012 S | 2,652,364 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 141 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| BUL · Pacer Funds Trust | 5.07% | 16,545 NS | July 31, 2026 | N-PORT |
| IHF · iShares Trust | 4.75% | 147,977 SH | Sept. 11, 2026 | Daily |
| STNC · Hennessy Funds Trust | 3.17% | 7,315 NS | July 31, 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 2.45% | 97,235 SH | Oct. 2, 2026 | Daily |
| COWZ · Pacer Funds Trust | 2.07% | 960,711 NS | July 31, 2026 | N-PORT |
| WLTG · ETF Opportunities Trust | 2.06% | 3,942 NS | July 31, 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.66% | 34,083 SH | Oct. 2, 2026 | Daily |
| RPG · Invesco Exchange-Traded Fund Trust | 1.27% | 58,580 SH | Oct. 2, 2026 | Daily |
| FLAG · Global X Funds | 1.14% | 48 NS | July 31, 2026 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1.03% | 6,909 NS | July 31, 2026 | N-PORT |
| IYH · iShares Trust | 1.01% | 87,417 SH | Sept. 11, 2026 | Daily |
| SRHQ · Elevation Series Trust | 0.94% | 4,938 NS | July 31, 2026 | N-PORT |
| NEAR · iShares U.S. ETF Trust | 0.92% | 48,109,000 SH | Sept. 11, 2026 | Daily |
| FHLC · FIDELITY COVINGTON TRUST | 0.91% | 74,445 NS | July 31, 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.90% | 470,451 SH | Aug. 19, 2026 | Daily |
| FXH · First Trust Exchange-Traded AlphaDE… | 0.87% | 22,725 NS | July 31, 2026 | N-PORT |
| DIVB · iShares Trust | 0.87% | 42,100 SH | Sept. 11, 2026 | Daily |
| NFRA · FlexShares Trust | 0.84% | 62,628 NS | July 31, 2026 | N-PORT |
| IXJ · iShares Trust | 0.83% | 81,708 SH | Sept. 11, 2026 | Daily |
| SPVM · Invesco Exchange-Traded Fund Trust | 0.80% | 2,483 SH | Oct. 2, 2026 | Daily |
| QUVU · Hartford Funds Exchange-Traded Trust | 0.79% | 3,522 NS | July 31, 2026 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0.78% | 23,458,000 | Oct. 2, 2026 | Daily |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0.74% | 25,897,000 | Oct. 1, 2026 | Daily |
| CURE · Direxion Shares ETF Trust | 0.72% | 3,056 NS | July 31, 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0.67% | 12,075 SH | Aug. 19, 2026 | Daily |
| LGDX · Tidal Trust III | 0.66% | 2,345 NS | July 31, 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0.55% | 11,876 SH | Aug. 19, 2026 | Daily |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0.50% | 23,126,000 | Oct. 2, 2026 | Daily |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0.46% | 7,404 NS | July 31, 2026 | N-PORT |
| WLDR · Two Roads Shared Trust | 0.43% | 964 NS | July 31, 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0.42% | 7,289 NS | July 31, 2026 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 0.40% | 92,161 SH | Oct. 2, 2026 | Daily |
| QLC · FlexShares Trust | 0.39% | 9,856 NS | July 31, 2026 | N-PORT |
| XOEF · iShares Trust | 0.37% | 194 SH | Sept. 11, 2026 | Daily |
| GSY · Invesco Actively Managed Exchange-T… | 0.36% | 14,000,000 | Oct. 2, 2026 | Daily |
| UPSD · ETF Series Solutions | 0.33% | 972 NS | July 31, 2026 | N-PORT |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0.33% | 9,324,000 | Oct. 2, 2026 | Daily |
| MGV · VANGUARD WORLD FUND | 0.29% | 97,604 SH | Aug. 19, 2026 | Daily |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0.28% | 390,000 | Oct. 2, 2026 | Daily |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.28% | 3,186 NS | July 31, 2026 | N-PORT |
| USXF · iShares Trust | 0.26% | 9,226 SH | Sept. 11, 2026 | Daily |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0.26% | 5,813 SH | Oct. 2, 2026 | Daily |
| IWX · iShares Trust | 0.23% | 21,535 SH | Sept. 11, 2026 | Daily |
| VTV · VANGUARD INDEX FUNDS | 0.23% | 1,475,731 SH | Aug. 19, 2026 | Daily |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0.23% | 14,235 NS | July 31, 2026 | N-PORT |
| MPLY · Strategy Shares | 0.22% | 87 NS | July 31, 2026 | N-PORT |
| EUSA · iShares, Inc. | 0.21% | 9,589 SH | Sept. 11, 2026 | Daily |
| RSP · Invesco Exchange-Traded Fund Trust | 0.21% | 462,724 SH | Oct. 2, 2026 | Daily |
| FTC · First Trust Exchange-Traded AlphaDE… | 0.20% | 6,420 NS | July 31, 2026 | N-PORT |
| SIZE · iShares Trust | 0.19% | 1,920 SH | Sept. 11, 2026 | Daily |
| DYNF · BlackRock ETF Trust | 0.19% | 183,934 SH | Sept. 11, 2026 | Daily |
| VMAX · Lattice Strategies Trust | 0.19% | 228 NS | July 31, 2026 | N-PORT |
| DSI · iShares Trust | 0.19% | 23,734 SH | Sept. 11, 2026 | Daily |
| ILCV · iShares Trust | 0.18% | 5,870 SH | Sept. 10, 2026 | Daily |
| IVW · iShares Trust | 0.18% | 331,185 SH | Sept. 11, 2026 | Daily |
| IUSG · iShares Trust | 0.17% | 136,713 SH | Sept. 11, 2026 | Daily |
| VOOG · VANGUARD ADMIRAL FUNDS | 0.17% | 115,334 SH | Aug. 19, 2026 | Daily |
| IWD · iShares Trust | 0.17% | 332,035 SH | Sept. 11, 2026 | Daily |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.16% | 90,157 SH | Aug. 19, 2026 | Daily |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0.16% | 17,773 SH | Oct. 2, 2026 | Daily |
| USMV · iShares Trust | 0.16% | 89,855 SH | Sept. 11, 2026 | Daily |
| ACWV · iShares, Inc. | 0.15% | 11,903 SH | Sept. 11, 2026 | Daily |
| EGLE · Global X Funds | 0.15% | 8 NS | July 31, 2026 | N-PORT |
| GLBL · Pacer Funds Trust | 0.15% | 4 NS | July 31, 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0.14% | 33,327 SH | Oct. 2, 2026 | Daily |
| VOXP · Advisors Series Trust | 0.13% | 18 NS | July 31, 2026 | N-PORT |
| VRIG · Invesco Actively Managed Exchange-T… | 0.12% | 2,250,000 | Oct. 1, 2026 | Daily |
| TOPC · iShares Trust | 0.12% | 95 SH | Sept. 11, 2026 | Daily |
| DGRO · iShares Trust | 0.12% | 120,741 SH | Sept. 11, 2026 | Daily |
| XVV · iShares Trust | 0.11% | 1,790 SH | Sept. 11, 2026 | Daily |
| QVML · Invesco Exchange-Traded Fund Trust … | 0.11% | 4,410 SH | Oct. 2, 2026 | Daily |
| IWL · iShares Trust | 0.11% | 5,786 SH | Sept. 11, 2026 | Daily |
| MGC · VANGUARD WORLD FUND | 0.11% | 31,176 SH | Aug. 19, 2026 | Daily |
| ACIO · ETF Series Solutions | 0.11% | 6,205 NS | July 31, 2026 | N-PORT |
| EVUS · iShares Trust | 0.10% | 934 SH | Sept. 11, 2026 | Daily |
| ADME · ETF Series Solutions | 0.10% | 751 NS | July 31, 2026 | N-PORT |
| XRMI · Global X Funds | 0.10% | 126 NS | July 31, 2026 | N-PORT |
| XCLR · Global X Funds | 0.10% | 9 NS | July 31, 2026 | N-PORT |
| XYLD · Global X Funds | 0.10% | 8,148 NS | July 31, 2026 | N-PORT |
| XTR · Global X Funds | 0.10% | 12 NS | July 31, 2026 | N-PORT |
| BKLC · BNY Mellon ETF Trust | 0.10% | 13,621 NS | July 31, 2026 | N-PORT |
| VV · VANGUARD INDEX FUNDS | 0.10% | 181,364 SH | Aug. 19, 2026 | Daily |
| ESGV · VANGUARD WORLD FUND | 0.10% | 33,758 SH | Aug. 19, 2026 | Daily |
| IVV · iShares Trust | 0.10% | 1,957,485 SH | Sept. 11, 2026 | Daily |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0.10% | 26,839 SH | Oct. 2, 2026 | Daily |
| PTLC · Pacer Funds Trust | 0.10% | 7,919 NS | July 31, 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.10% | 1,395 NS | July 31, 2026 | N-PORT |
| PBP · Invesco Exchange-Traded Fund Trust | 0.10% | 877 SH | Oct. 2, 2026 | Daily |
| ILCB · iShares Trust | 0.10% | 2,915 SH | Sept. 11, 2026 | Daily |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0.10% | 1,794 SH | Oct. 2, 2026 | Daily |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.09% | 20,766 NS | July 31, 2026 | N-PORT |
| IYY · iShares Trust | 0.09% | 6,693 SH | Sept. 11, 2026 | Daily |
| VOTE · TCW ETF Trust | 0.09% | 2,545 NS | July 31, 2026 | N-PORT |
| FEX · First Trust Exchange-Traded AlphaDE… | 0.09% | 3,614 NS | July 31, 2026 | N-PORT |
| XYLG · Global X Funds | 0.09% | 147 NS | July 31, 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.09% | 46,791 NS | July 31, 2026 | N-PORT |
| IWB · iShares Trust | 0.09% | 103,721 SH | Sept. 11, 2026 | Daily |
| VOO · VANGUARD INDEX FUNDS | 0.09% | 4,034,357 SH | Aug. 19, 2026 | Daily |
| TOV · EA Series Trust | 0.09% | 607 NS | July 31, 2026 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0.09% | 586 NS | July 31, 2026 | N-PORT |
| ITOT · iShares Trust | 0.09% | 202,387 SH | Sept. 11, 2026 | Daily |
| ACVF · ETF Opportunities Trust | 0.09% | 337 NS | July 31, 2026 | N-PORT |
| GTOS · Invesco Actively Managed Exchange-T… | 0.09% | 104,000 | Oct. 2, 2026 | Daily |
| QDPL · Pacer Funds Trust | 0.09% | 3,708 NS | July 31, 2026 | N-PORT |
| IWV · iShares Trust | 0.09% | 41,034 SH | Sept. 11, 2026 | Daily |
| DFAU · Dimensional ETF Trust | 0.08% | 25,516 NS | July 31, 2026 | N-PORT |
| CRBN · iShares Trust | 0.08% | 2,269 SH | Sept. 11, 2026 | Daily |
| TOK · iShares Trust | 0.08% | 451 SH | Sept. 11, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.08% | 4,930,930 SH | Aug. 19, 2026 | Daily |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.08% | 24,633 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.08% | 12,577 SH | Aug. 19, 2026 | Daily |
| PHDG · Invesco Actively Managed Exchange-T… | 0.08% | 116 SH | Oct. 2, 2026 | Daily |
| HCMT · Direxion Shares ETF Trust | 0.08% | 1,081 NS | July 31, 2026 | N-PORT |
| TILT · FlexShares Trust | 0.08% | 4,108 NS | July 31, 2026 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0.07% | 12,141 NS | July 31, 2026 | N-PORT |
| URTH · iShares, Inc. | 0.07% | 14,079 SH | Sept. 11, 2026 | Daily |
| ACWI · iShares Trust | 0.06% | 50,294 SH | Sept. 11, 2026 | Daily |
| HDUS · Lattice Strategies Trust | 0.05% | 275 NS | July 31, 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.05% | 125,729 SH | Aug. 19, 2026 | Daily |
| DCOR · Dimensional ETF Trust | 0.05% | 3,816 NS | July 31, 2026 | N-PORT |
| GLOF · iShares Trust | 0.04% | 202 SH | Sept. 11, 2026 | Daily |
| DUHP · Dimensional ETF Trust | 0.04% | 10,761 NS | July 31, 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.02% | 28,662 NS | July 31, 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0.02% | 1,127 NS | July 31, 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.01% | 99 NS | July 31, 2026 | N-PORT |
| GTO · Invesco Actively Managed Exchange-T… | 0.00% | 42,000 | Sept. 30, 2026 | Daily |
| CBLS · Elevation Series Trust | -1.12% | -1,546 NS | July 31, 2026 | N-PORT |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| BLV · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| BND · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| VUSB · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| VCRB · VANGUARD MALVERN FUNDS | · | · | July 15, 2026 | Daily |
| VPLS · VANGUARD MALVERN FUNDS | · | · | July 15, 2026 | Daily |
| VSDB · VANGUARD MALVERN FUNDS | · | · | July 15, 2026 | Daily |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | July 15, 2026 | Daily |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | July 15, 2026 | Daily |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | July 15, 2026 | Daily |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | July 30, 2026 | Daily |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | July 30, 2026 | Daily |
| VCEB · VANGUARD WORLD FUND | · | · | July 30, 2026 | Daily |
HCA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
22 analysts · 2026-09-28Mean target $454.23 +6.5%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| HCA | $104.86B | 16.5 | 7.1% | 9.0% | -159.1% | · |
| THC | $17.28B | 12.8 | 3.1% | 11.1% | 56.4% | · |
| EHC | $10.61B | 19.2 | 10.5% | 9.5% | 25.1% | · |
| UHS | · | 9.4 | 9.7% | 8.6% | 21.4% | · |
| ENSG | $10.12B | 29.8 | 18.7% | 6.8% | 16.9% | · |
| PACS | $6.01B | 31.5 | 29.3% | 3.6% | 23.1% | · |
| CON | $2.53B | 15.1 | 13.9% | 7.7% | 49.8% | · |
| BKD | $2.57B | -9.6 | 2.2% | -8.2% | -313.2% | 26.2% |
| ACHC | $1.28B | -1.2 | 5.0% | -33.3% | -43.9% | · |
| SNDA | $612M | -7.7 | 25.2% | -18.6% | -197.2% | · |
Latest News Recent headlines mentioning this company
Trading Signals Recent buy/sell signals with entry price and risk/reward ratio
No open signal right now — no card is filled, and that's honest.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.